Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Hepatology. 2013 Feb;57(2):708–715. doi: 10.1002/hep.26067

Figure 4.

Figure 4

Effects of CTLA4-Ig treatment on 2OA-BSA-induced cholangitis. 2OA-BSA immunized mice were treated with CTLA4-Ig for 4 weeks, started 8 weeks after initial immunization (2OA+CTLA). 2OA-BSA immunized mice without CTLA treatment were utilized as control group (2OA). (A) H&E-stained representative liver sections. (B) Scores of intrahepatic bile duct damage in 2OA-immunized mice with or without CTLA4-Ig treatment. Each group included 12 mice. *, p < 0.05 (Chi-squared test for independence).